Pfizer prevails in COX-2 patent case
Executive Summary
A University of Rochester patent claiming the use of COX-2 inhibitors to treat inflammation is invalid because it failed to identify the compounds claimed, a federal appeals court says in a 1ruling for Pfizer. The university sued Pfizer in 2000, alleging that the sale of the COX-2 inhibitors Celebrex (celecoxib) and Bextra (valdecoxib) infringed the patent (2"The Pink Sheet" April 17, 2000, p. 14)...
You may also be interested in...
Pharmacia Preparing Defense Against Rochester COX-2 Patent Challenge
Pharmacia is preparing to defend itself against a COX-2 inhibitor patent infringement suit brought by the University of Rochester rather than agreeing to pay royalties to the university.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.